MindImmune Therapeutics, Inc.
PrivateLast Round
VC Round
Mar 10, 2026
Est. Valuation
$22.4M
Total Funding Raised
$23.6M
Company Overview
MindImmune Therapeutics, Inc. is a biotechnology company that develops antibody-based drugs and therapeutics designed to treat diseases of the central nervous system by targeting neuroinflammation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MindImmune Therapeutics, Inc. Comps
Public and private peers based on sector, stage, and business model.
MindImmune Therapeutics, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Mar 10, 2026 | ||||
| Series A Extension | Nov 24, 2025 | ||||
| Grant | Jun 1, 2025 | ||||
| Series A | Jun 14, 2022 | ||||
| Seed | Aug 21, 2017 | ||||
Seed | Jul 14, 2016 |
Key People
Founding team and executive leadership
MindImmune Therapeutics, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Dolby Family Ventures | Series A, Series A Extension |
| Rhode Island Life Science Hub | Grant |
| Pfizer Ventures | Series A Extension, Series A |
| RightHill Ventures | Series A Extension, Series A |
| Pfizer | Series A |
| Slater Technology Fund | Series A Extension, Seed |
| Gates Frontier | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 10, 2026
Raised $5M in a VC Round.
- Nov 26, 2025
Isaac Stoner appointed as the new Chief Executive Officer.
MindImmune Therapeutics, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about MindImmune Therapeutics, Inc.'s valuation, stock price, and market status.
